Imricor Medical Systems (ASX:IMR) said the Lausanne University Hospital in Switzerland performed its first procedure using the company's iCMR cardiac ablation device, according to a Wednesday filing with the Australian bourse.
The move makes the hospital the third site for the company's Visabl-AFL clinical trial being conducted to support the US Food and Drug Administration approval of the company's products, the filing said. It follows the activation of the Johns Hopkins Hospital in the US and the Cardiovascular Institute of South Paris in France.
The company's shares rose past 11% in recent Wednesday trade and earlier hit their highest since November 2021.
Price (AUD): $0.98, Change: $+0.10, Percent Change: +11.36%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。